Kuprys-Lipinska, Izabela
Kolacinska-Flont, Marta
Kuna, Piotr
Article History
Received: 31 October 2019
Accepted: 13 April 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: Not applicable.
: All authors provided written consent for the publication of this article. No personal patient data requiring consent for publication were used.
: IK-L received personal fees for lectures from AstraZeneca, Chiesi, GSK, Nexter, Novartis and Teva; PK received personal fees for lectures from Adamed, Allergopharma, Almirall, Astra- Zeneca, GSK, HAL, Meda, Pfizer, Polfarmex, Stallergen, Teva, and LekAM, and for lectures and advisory board activities from Boehringer Ingelheim, Celon Pharma, Chiesi, FAES, MSD, Novartis, and Polpharma. MK-F received personal fees for lectures from AstraZeneca and Novartis.